Business Wire07.25.18
Riverain Technologies, an innovator in proprietary image analysis and machine learning technologies, has been awarded a broad patent for its technology that forms a vessel suppressed, chest computed tomography series using deep learning and synthetic data modeling.
The patent holds significant promise for improving the detection and diagnosis of lung cancer at an earlier stage while making clinicians more efficient, a first for computer-aided detection.
Riverain has been issued U.S. Patent 9,990,743 for its methodology to selectively remove anatomical structures from CT scans to optimize reading accuracy and efficiency for lung cancer detection. The technology is used in the company’s software, ClearRead CT, which has been shown to lead to more accurate and efficient detection of lung nodules (an early lung cancer indicator). A range of possible applications exists within other imaging modalities including magnetic resonance imaging, positron emission tomography (PET), full field digital mammography and tomosynthesis, where normal structures interfere with the detection and diagnosis of disease.
Riverain Technologies is a clinical AI software innovator that develops solutions to aid clinicians in the early detection of disease. The company is based in Miamisburg, Ohio.
The patent holds significant promise for improving the detection and diagnosis of lung cancer at an earlier stage while making clinicians more efficient, a first for computer-aided detection.
Riverain has been issued U.S. Patent 9,990,743 for its methodology to selectively remove anatomical structures from CT scans to optimize reading accuracy and efficiency for lung cancer detection. The technology is used in the company’s software, ClearRead CT, which has been shown to lead to more accurate and efficient detection of lung nodules (an early lung cancer indicator). A range of possible applications exists within other imaging modalities including magnetic resonance imaging, positron emission tomography (PET), full field digital mammography and tomosynthesis, where normal structures interfere with the detection and diagnosis of disease.
Riverain Technologies is a clinical AI software innovator that develops solutions to aid clinicians in the early detection of disease. The company is based in Miamisburg, Ohio.